智翔金泰：GR2301注射液获得药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression dysregulation [1] Group 1 - The clinical trial application for GR2301 injection has been approved [1] - GR2301 injection is developed independently by the company [1] - The mechanism of GR2301 involves blocking IL-15 from binding to its receptors, thereby inhibiting the downstream IAK-STAT signaling pathway [1]